{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:41:02Z","timestamp":1780087262313,"version":"3.54.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100008091","name":"Golestan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10067-021-05698-4","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T04:06:40Z","timestamp":1617336400000},"page":"3897-3918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Maliheh","family":"Moradzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mehrbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Arab-Bafrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafiseh","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"5698_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390:1685\u20131699","journal-title":"Lancet"},{"key":"5698_CR2","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan S, Distler JHW, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:1188\u20131194","journal-title":"Ann Rheum Dis"},{"key":"5698_CR3","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/ar2965","volume":"12","author":"S Bosello","year":"2010","unstructured":"Bosello S, De Santis M, Lama G, Span\u00f2 C, Angelucci C, Tolusso B, Sica G, Ferraccioli G (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12:R54","journal-title":"Arthritis Res Ther"},{"key":"5698_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/rheumatology\/key175","volume":"57","author":"N Pittman","year":"2018","unstructured":"Pittman N, Rawn SM, Wang M, Masetto A, Beattie KA, Larch\u00e9 M (2018) Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology 57:1802\u20131811","journal-title":"Rheumatology"},{"key":"5698_CR5","first-page":"1624","volume":"390","author":"The L","year":"2017","unstructured":"The L (2017) Systemic sclerosis: advances and prospects. Lancet (London, England) 390:1624","journal-title":"Lancet (London, England)"},{"key":"5698_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13075-016-1017-y","volume":"18","author":"D Daoussis","year":"2016","unstructured":"Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, Andonopoulos AP, Liossis S-N (2016) B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 18:118","journal-title":"Arthritis Res Ther"},{"key":"5698_CR7","doi-asserted-by":"crossref","unstructured":"Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, Pirronti T, Ferraccioli G (2015) Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. In: Seminars in arthritis and rheumatism vol 4. Elsevier, pp 428-436","DOI":"10.1016\/j.semarthrit.2014.09.002"},{"key":"5698_CR8","doi-asserted-by":"crossref","unstructured":"Bellan M, Patrucco F, Barone-Adesi F, Gavelli F, Castello LM, Nerviani A, Andreoli L, Cavagna L, Pirisi M, Sainaghi PP (2019) Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: a systematic review. Autoimmun Rev:102453","DOI":"10.1016\/j.autrev.2019.102453"},{"key":"5698_CR9","doi-asserted-by":"publisher","first-page":"106389","DOI":"10.1016\/j.intimp.2020.106389","volume":"83","author":"R Tang","year":"2020","unstructured":"Tang R, Yu J, Shi Y, Zou P, Zeng Z, Tang B, Wang Y, Ling G, Luo M, Xiao R (2020) Safety and efficacy of Rituximab in systemic sclerosis: a systematic review and meta-analysis. Int Immunopharmacol 83:106389","journal-title":"Int Immunopharmacol"},{"key":"5698_CR10","first-page":"S17","volume":"30","author":"D Daoussis","year":"2012","unstructured":"Daoussis D, Liossis S, Tsamandas A, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos A (2012) Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 30:S17","journal-title":"Clin Exp Rheumatol"},{"key":"5698_CR11","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","volume":"57","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology 57:2106\u20132113","journal-title":"Rheumatology"},{"key":"5698_CR12","first-page":"S142","volume":"36","author":"P Fraticelli","year":"2018","unstructured":"Fraticelli P, Fischetti C, Salaffi F, Carotti M, Mattioli M, Pomponio G, Gabrielli A (2018) Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study. Clin Exp Rheumatol 36:S142\u2013S145","journal-title":"Clin Exp Rheumatol"},{"key":"5698_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2014-eular.6319","volume":"73","author":"JA Sancho","year":"2014","unstructured":"Sancho JA, Narv\u00e1ez J, Castellv\u00ed I, Herrera S, Molina M, Castillo D, Rodr\u00edguez JO, De la Morena BI, Villarino MR, Pascual EV (2014) FRI0485 Long-term efficacy of rituximab in systemic sclerosis. A Spanish multicentric analysis. Ann Rheum Dis 73:563\u2013563","journal-title":"Ann Rheum Dis"},{"key":"5698_CR14","doi-asserted-by":"publisher","first-page":"A648","DOI":"10.1136\/annrheumdis-2013-eular.1924","volume":"72","author":"L Ananyeva","year":"2013","unstructured":"Ananyeva L, Desinova O, Starovoytova M, Koneva O, Yutkina N, Onsyannikova O, Volkov A, Aleksandrova E (2013) SAT0198 Rituximab for the treatment of systemic sclerosis associated interstitial lung disease: a case series. Ann Rheum Dis 72:A648\u2013A648","journal-title":"Ann Rheum Dis"},{"key":"5698_CR15","first-page":"237","volume":"71","author":"D Daoussis","year":"2013","unstructured":"Daoussis D, Liossis S-N, Antonopoulos I, Markatseli T, Yiannopoulos G, Drosos A, Andonopoulos A (2013) THU0245 Rituximab has a beneficial effect on lung function and skin fibrosis in patients with systemic sclerosis. An open label study. Ann Rheum Dis 71:237\u2013238","journal-title":"Ann Rheum Dis"},{"key":"5698_CR16","doi-asserted-by":"crossref","unstructured":"Guzelant G, Melikoglu M, Musellim B, Yilmaz D, Fresko I, Seyahi E, Hatemi G, Ugurlu S, Hamuryudan V (2017) AB0634 Rituximab in systemic sclerosis-interstitial lung disease, a case series of 18 patients. BMJ Publishing Group Ltd,","DOI":"10.1136\/annrheumdis-2017-eular.4908"},{"key":"5698_CR17","doi-asserted-by":"crossref","unstructured":"Melissaropoulos K, Daoussis D, Antonopoulos I, Markatseli T, Georgiou P, Yiannopoulos G, Drosos A, Andonopoulos A, Liossis S (2015) SAT0450 Rituximab in systemic sclerosis. Results of an up to seven years, open label, multicenter study with a follow-up of 89 patient-years. BMJ Publishing Group Ltd,","DOI":"10.1136\/annrheumdis-2015-eular.4618"},{"key":"5698_CR18","doi-asserted-by":"crossref","unstructured":"Kiryttopoulos P, Michailidis T, Papchianou E, Charalampidis M, Dimitriadis P, Agorastos A (2017) FRI0412 The positive effect of rituximab in pulmonary fibrosis of systemic sclerosis. BMJ Publishing Group Ltd,","DOI":"10.1136\/annrheumdis-2017-eular.6398"},{"key":"5698_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","volume":"17","author":"M Thiebaut","year":"2018","unstructured":"Thiebaut M, Launay D, Riviere S, Mah\u00e9vas T, Bellakhal S, Hachulla E, Fain O, Mekinian A (2018) Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev 17:582\u2013587","journal-title":"Autoimmun Rev"},{"key":"5698_CR20","first-page":"181","volume":"34","author":"G Lepri","year":"2016","unstructured":"Lepri G, Avouac J, Air\u00f2 P, Anguita Santos F, Bellando-Randone S, Blagojevic J, Garcia Hern\u00e0ndez F, Gonzalez Nieto JA, Guiducci S, Jordan S (2016) Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol 34:181\u2013185","journal-title":"Clin Exp Rheumatol"},{"key":"5698_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","volume":"1","author":"A Booth","year":"2012","unstructured":"Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart L (2012) The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 1:2","journal-title":"Syst Rev"},{"key":"5698_CR22","unstructured":"Moradzadeh M, Aghaei M, Mehrbakhsh Z, Abdollahi N, Arab Bafrani Z (2018) Efficacy and safety of Rituximab therapy for patients with systemic sclerosis disease (SSc): systematic review and meta-analysis [CRD42018103751]."},{"key":"5698_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"key":"5698_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang A-G, Buchner A (2007) G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175\u2013191","journal-title":"Behav Res Methods"},{"key":"5698_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, Kuss O, Higgins JP, Langan D, Salanti G (2016) Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods 7:55\u201379","journal-title":"Res Synth Methods"},{"key":"5698_CR26","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1890\/11-0423.1","volume":"92","author":"MJ Lajeunesse","year":"2011","unstructured":"Lajeunesse MJ (2011) On the meta-analysis of response ratios for studies with correlated and multi-group designs. Ecology 92:2049\u20132055","journal-title":"Ecology"},{"key":"5698_CR27","doi-asserted-by":"crossref","unstructured":"Borenstein M, Hedges LV, Higgins J, Rothstein HR (2009) Converting among effect sizes. Introduction to Meta-analysis:45\u201349","DOI":"10.1002\/9780470743386"},{"key":"5698_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Bmj 327:557\u2013560","journal-title":"Bmj"},{"key":"5698_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.24249","volume":"60","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578\u2013583","journal-title":"Arthritis Rheum"},{"key":"5698_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","volume":"49","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis S-NC, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49:271\u2013280","journal-title":"Rheumatology"},{"key":"5698_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3899\/jrheum.120778","volume":"40","author":"V Smith","year":"2013","unstructured":"Smith V, Piette Y, Van Praet JT, Decuman S, Deschepper E, Elewaut D, De Keyser F (2013) Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 40:52\u201357","journal-title":"J Rheumatol"},{"key":"5698_CR32","doi-asserted-by":"crossref","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L A (2017) multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. In: Seminars in arthritis and rheumatism vol 5. Elsevier, pp 625-631","DOI":"10.1016\/j.semarthrit.2016.10.003"},{"key":"5698_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/17843286.2017.1372244","volume":"73","author":"K Melsens","year":"2018","unstructured":"Melsens K, Vandecasteele E, Deschepper E, Badot V, Blockmans D, Brusselle G, De Langhe E, De Pauw M, Debusschere C, Decuman S (2018) Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clin Belg 73:119\u2013125","journal-title":"Acta Clin Belg"},{"key":"5698_CR34","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","volume":"14","author":"D Giuggioli","year":"2015","unstructured":"Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C (2015) Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature Autoimmunity reviews 14:1072\u20131078","journal-title":"Our experience and review of the literature Autoimmunity reviews"},{"key":"5698_CR35","doi-asserted-by":"crossref","unstructured":"Sari A, Guven D, Armagan B, Kilic L, Erden A, Akdogan A (2017) AB0604 Rituximab experience in patients with longstanding systemic sclerosis-associated interstitial lung disease: a series of 14 patients. BMJ Publishing Group Ltd,","DOI":"10.1136\/annrheumdis-2017-eular.5501"},{"key":"5698_CR36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Sancho JJA, Truchetet M-E, Braun-Moscovici Y, Iannone F, Novikov PI (2019) Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 78:979\u2013987","journal-title":"Ann Rheum Dis"},{"key":"5698_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/1346-8138.15079","volume":"46","author":"S Ebata","year":"2019","unstructured":"Ebata S, Yoshizaki A, Fukasawa T, Miura S, Takahashi T, Sumida H, Asano Y, Sato S (2019) Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol 46:1006\u20131013","journal-title":"J Dermatol"},{"key":"5698_CR38","doi-asserted-by":"crossref","unstructured":"Jordan S, Distler JH, Maurer B, Huscher D, Van Laar JM, Allanore Y, Distler O, group ERs (2014) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of the Rheumatic diseases:annrheumdis-2013-204522","DOI":"10.1136\/annrheumdis-2013-204522"},{"key":"5698_CR39","doi-asserted-by":"crossref","unstructured":"Vilela VS, Maretti GB, Gama LMdS, Costa CHd, Rufino RL, Levy RA (2016) Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Rev Bras Reumatol 56:458-463","DOI":"10.1016\/j.rbre.2016.06.003"},{"key":"5698_CR40","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1002\/art.22967","volume":"56","author":"YO Teng","year":"2007","unstructured":"Teng YO, Levarht EN, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM (2007) Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 56:3909\u20133918","journal-title":"Arthritis Rheum"},{"key":"5698_CR41","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3899\/jrheum.150869","volume":"43","author":"S Edginton","year":"2016","unstructured":"Edginton S, Hitchon C, Froese W, El-Gabalawy H (2016) Effects of Rituximab and Infliximab treatment on carboxypeptidase B and its substrates in RA synovium. J Rheumatol 43:846\u2013854","journal-title":"J Rheumatol"},{"key":"5698_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/RHU.0000000000000584","volume":"23","author":"A Sari","year":"2017","unstructured":"Sari A, Guven D, Armagan B, Erden A, Kalyoncu U, Karadag O, Bilgen SA, Ertenli I, Kiraz S, Akdogan A (2017) Rituximab experience in patients with long-standing systemic sclerosis\u2013associated interstitial lung disease: a series of 14 patients. J Clin Rheumatol 23:411\u2013415","journal-title":"J Clin Rheumatol"},{"key":"5698_CR43","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","volume":"43","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437\u20132444","journal-title":"Arthritis Rheum"},{"key":"5698_CR44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/ard.2008.095463","volume":"69","author":"V Smith","year":"2010","unstructured":"Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert J-M, Decuman S, Elewaut D, De Keyser F (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193\u2013197","journal-title":"Ann Rheum Dis"},{"key":"5698_CR45","doi-asserted-by":"publisher","first-page":"v53","DOI":"10.1093\/rheumatology\/kex202","volume":"56","author":"G Kum\u00e1novics","year":"2017","unstructured":"Kum\u00e1novics G, P\u00e9ntek M, Bae S, Opris D, Khanna D, Furst DE, Czirj\u00e1k L (2017) Assessment of skin involvement in systemic sclerosis. Rheumatology 56:v53\u2013v66","journal-title":"Rheumatology"},{"key":"5698_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"D Khanna","year":"2017","unstructured":"Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M (2017) Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2:11\u201318","journal-title":"J Scleroderma Relat Disord"},{"key":"5698_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40744-019-00181-8","volume":"7","author":"SL Gale","year":"2020","unstructured":"Gale SL, Trinh H, Mathew N, Jahreis A, Lin CJF, Sarsour K (2020) Characterizing disease manifestations and treatment patterns among adults with systemic sclerosis: a retrospective analysis of a US healthcare claims population. Rheumatol Ther 7:89\u201399","journal-title":"Rheumatol Ther"},{"key":"5698_CR48","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"5698_CR49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","volume":"18","author":"P Saunders","year":"2017","unstructured":"Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU (2017) Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials 18:275","journal-title":"Trials"},{"key":"5698_CR50","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet M-E, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellv\u00ed I, Air\u00f3 P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, L\u00f3pez-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold A-M, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y (2019) Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 78:979\u2013987","journal-title":"Ann Rheum Dis"},{"key":"5698_CR51","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L, Liossis S-N (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 46:625\u2013631","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05698-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05698-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05698-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T21:55:47Z","timestamp":1632520547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05698-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5698"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05698-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"23 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}